What is it about?
The apathy and frailty are risk factors in Alzheimer's disease (AD) progresses. However, there is currently no effective drug for treating both anorexia and apathy in AD. Here, we conducted an open-label pilot study to determine whether ninjin’yoeito (NYT, TJ-108), a multicomponent drug, is effective for improving anorexia and apathy in patients with AD, and consequently their cognitive function. After treatment, significant improvements were observed in the scores for “anorexia” and “apathy” by NPI, meal ingestion amount and cognitive dysfunction by MMSE.
Featured Image
Why is it important?
We propose that NYT, a multicomponent drug with several effects including dopamine modulation, is a new-type dementia therapeutic agent with low risk of adverse reactions that can improve simultaneously anorexia/apathy, as well as cognitive dysfunction in frail AD patients.
Perspectives
Given that NYT also improves cerebral blood flow involving both suppression of Aβproduction via beta-site APP cleaving enzyme-1 (BACE1) and acceleration of Aβ excretion from the brain, it may also have beneficial effects in patients with mild cognitive impairment (MCI) with apathy and white matter changes or cognitive frail patients, namely in the prevention of dementia.
Makoto Ohsawa
Read the Original
This page is a summary of: A Possibility of Simultaneous Treatment with the Multicomponent Drug, Ninjin’yoeito, for Anorexia, Apathy, and Cognitive Dysfunction in Frail Alzheimer’s Disease Patients: An Open-Label Pilot Study, Journal of Alzheimer s Disease Reports, December 2017, IOS Press,
DOI: 10.3233/adr-170026.
You can read the full text:
Contributors
The following have contributed to this page
